Algorithms designed to identify canonical yeast prions predict that around 250 human proteins, including several RNA-binding proteins associated with neurodegenerative disease, harbour a distinctive prion-like domain (PrLD) enriched in uncharged polar amino acids and glycine. PrLDs in RNA-binding proteins are essential for the assembly of ribonucleoprotein granules. However, the interplay between human PrLD function and disease is not understood. Here we define pathogenic mutations in PrLDs of heterogeneous nuclear ribonucleoproteins (hnRNPs) A2B1 and A1 in families with inherited degeneration affecting muscle, brain, motor neuron and bone, and in one case of familial amyotrophic lateral sclerosis. Wild-type hnRNPA2 (the most abundant isoform of hnRNPA2B1) and hnRNPA1 show an intrinsic tendency to assemble into self-seeding fibrils, which is exacerbated by the disease mutations. Indeed, the pathogenic mutations strengthen a 'steric zipper' motif in the PrLD, which accelerates the formation of self-seeding fibrils that cross-seed polymerization of wild-type hnRNP. Notably, the disease mutations promote excess incorporation of hnRNPA2 and hnRNPA1 into stress granules and drive the formation of cytoplasmic inclusions in animal models that recapitulate the human pathology. Thus, dysregulated polymerization caused by a potent mutant steric zipper motif in a PrLD can initiate degenerative disease. Related proteins with PrLDs should therefore be considered candidates for initiating and perhaps propagating proteinopathies of muscle, brain, motor neuron and bone.
Algorithms designed to identify canonical yeast prions predict that around 250 human proteins, including several RNA-binding proteins associated with neurodegenerative disease, harbour a distinctive prion-like domain (PrLD) enriched in uncharged polar amino acids and glycine. PrLDs in RNA-binding proteins are essential for the assembly of ribonucleoprotein granules. However, the interplay between human PrLD function and disease is not understood. Here we define pathogenic mutations in PrLDs of heterogeneous nuclear ribonucleoproteins (hnRNPs) A2B1 and A1 in families with inherited degeneration affecting muscle, brain, motor neuron and bone, and in one case of familial amyotrophic lateral sclerosis. Wild-type hnRNPA2 (the most abundant isoform of hnRNPA2B1) and hnRNPA1 show an intrinsic tendency to assemble into self-seeding fibrils, which is exacerbated by the disease mutations. Indeed, the pathogenic mutations strengthen a 'steric zipper' motif in the PrLD, which accelerates the formation of self-seeding fibrils that cross-seed polymerization of wild-type hnRNP. Notably, the disease mutations promote excess incorporation of hnRNPA2 and hnRNPA1 into stress granules and drive the formation of cytoplasmic inclusions in animal models that recapitulate the human pathology. Thus, dysregulated polymerization caused by a potent mutant steric zipper motif in a PrLD can initiate degenerative disease. Related proteins with PrLDs should therefore be considered candidates for initiating and perhaps propagating proteinopathies of muscle, brain, motor neuron and bone.
Elucidating the genetic basis of rare, inherited diseases can provide valuable insights to the molecular pathogenesis of common diseases. Inclusion body myopathy (IBM) associated with Paget's disease of the bone (PDB), fronto-temporal dementia (FTD) and amyotrophic lateral sclerosis (ALS)-sometimes called IBMPFD/ALS-is a rare disorder characterized by progressive degeneration of muscle, brain, motor neurons and bone accompanied by prominent TDP-43 (also called TARDBP) pathology 1 . Patients with this rare, inherited syndrome experience features of IBM, FTD, ALS or PDB indistinguishable from familial and sporadic cases of these disorders, and the disease may manifest in several tissues in the same patient 1, 2 . Recently the name multisystem proteinopathy (MSP) has been adopted to reflect the expanding phenotype and prominent proteinaceous pathology that characterizes this syndrome. Some, but not all, cases of MSP are caused by mutations in the VCP gene 3 , which encodes the AAA1 ATPase VCP, a ubiquitin-dependent segregase.
The discovery that VCP mutations cause MSP led to the subsequent discovery of pathogenic VCP mutations in more common diseases such as sporadic or familial forms of ALS 2 , FTD 4 , IBM 5 and PDB 6 . These rare MSP families represent a unique opportunity to identify fundamental molecular defects shared among age-related diseases; thus it is highly desirable to identify additional genetic mutations responsible for this syndrome.
A pathogenic mutation in hnRNPA2B1 in MSP
We identified a family (family 1) with dominantly inherited degeneration affecting muscle, bone, brain and motor neurons that was clinically indistinguishable from previous families we have seen with VCP-related MSP ( Fig. 1a, Supplementary Fig. 1 and Supplementary  Table 1 ). Sequencing the entire VCP gene (including introns and exons) in affected patients revealed no synonymous or nonsynonymous variants. Genetic analysis of this family by exome sequencing and linkage analysis in parallel ( Supplementary Fig. 1 ) identified a single, previously unknown variant (c.869/905A.T, p.D290V/D302V) that co-segregates with disease and alters the gene encoding hnRNPA2B1, a ubiquitously expressed RNA-binding protein (Fig. 1a ). hnRNPA2B1 is expressed as two alternatively spliced isoforms: A2 and B1. The shorter hnRNPA2, which lacks 12 amino acids in the amino-terminal region, is the main isoform, accounting for ,90% of the protein in most tissues. The identified mutation substitutes a valine residue in the place of an evolutionarily conserved aspartate residue ( Fig. 1d ) that is centred in a motif conserved in multiple human paralogues of the hnRNP A/B family ( Fig. 1f and Supplementary Fig. 3 ).
Pathogenic mutations in hnRNPA1 in MSP and ALS
Additional validation of the pathogenicity of the hnRNPA2B1 mutation came from the analysis of family 2. The clinical features of this family with VCP-negative MSP have been previously described 7 . To identify the culprit mutation we took the same strategy as for family 1 (Supplementary Fig. 2 and Supplementary Table 2 ). This analysis identified five previously unknown single nucleotide variants and one indel that cosegregated with the disease. Of these, a mutation in hnRNPA1 (c.785/ 941A.T, p.D262V/D314V) stood out because it was the only variant associated with a conserved residue, it was predicted to be deleterious, and because hnRNPA1 is highly expressed in affected tissues ( Fig. 1b and Supplementary Fig. 2 ). Moreover, this mutation in hnRNPA1 was identical to that found in hnRNPA2B1 in family 1, creating a substitution of a valine residue in the place of a highly conserved aspartate residue that is centred in a motif conserved in multiple human paralogues of the hnRNP A/B family (Fig. 1e , f and Supplementary Fig. 3 ). Subsequent to the identification of these MSP-causing mutations we screened the exomes of 212 familial ALS cases for sequence variants affecting hnRNPA2B1 or hnRNPA1. In one dominantly inherited case in which known ALS genes were formally excluded, we identified a mutation (c.784/940G.A; p.D262N/D314N) affecting the identical, conserved aspartate residue in hnRNPA1 ( Fig. 1c , e, f).
The identification of disease mutations in hnRNPA2B1 and hnRNPA1 was intriguing for three reasons. First, hnRNPA2B1 and hnRNPA1 interact directly with TDP-43 and function cooperatively to regulate RNA metabolism 8 . Second, an unbiased genetic screen previously identified fly homologues of TDP-43, hnRNPA2B1 and hnRNPA1 as suppressors of VCP-related degeneration in a Drosophila model of MSP 9 ( Supplementary Fig. 3 ). Last, hnRNPA2B1 has been previously implicated in neurodegenerative disease. Specifically, hnRNPA2B1 is sequestered in RNA foci in the fragile-X-associated tremor ataxia syndrome (FXTAS) 10 , binds the expanded riboCGG repeats that underlie this disease 11, 12 , and is a genetic modifier in a Drosophila model of FXTAS 11,12 . hnRNPA2B1 and hnRNPA1 pathology in MSP Muscle biopsies from patients II5 (family 1) and IV9 (family 2) showed atrophic fibres, central nuclei and rimmed vacuoles characteristic of IBM ( Supplementary Fig. 4a -c). Whereas in normal muscle hnRNPA2B1 and hnRNPA1 are exclusively nuclear ( Fig. 2a, e and Supplementary Fig. 4d ), analysis of muscle tissue from patient II5 showed that hnRNPA2B1 cleared from many nuclei and accumulated in cytoplasmic inclusions in ,10% of fibres ( Fig. 2b and Supplementary Fig. 4e ). Muscle from this patient also showed TDP-43 pathology consisting of nuclear clearance and cytoplasmic inclusions, consistent with previous observations in VCP-related and sporadic IBM ( Fig. 2j and Supplementary Fig. 4p ) 13 . Interestingly, hnRNPA2B1 pathology was also observed in VCP-related and sporadic IBM (Fig. 2c, d and Supplementary Fig. 4h , i).
Analysis of muscle from patient IV9 also revealed nuclear clearance and cytoplasmic inclusions of hnRNPA1 in ,10% of fibres ( Fig. 2f and Supplementary Fig. 4j ). hnRNPA2B1 and TDP-43 pathology were also observed in the muscle biopsy from patient IV9 (Fig. 2h , k and Supplementary Fig. 4f , g). Moreover, hnRNPA1 pathology was also observed in VCP-related and sporadic IBM ( Fig. 2g and data not shown). Therefore, regardless of aetiology we have found hnRNPA2B1, hnRNPA1 and TDP-43 pathology in sporadic and familial IBM. Pathological redistribution of hnRNPA2B1, hnRNPA1 and TDP-43 was not observed in other types of muscle disease (Supplementary Fig. 4q ). FUS (also known as TLS)-associated pathology was not observed in these cases, and thus pathological redistribution 
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does not affect all hnRNPs. Double staining revealed that fibres with TDP-43 pathology typically also showed hnRNPA2B1 and hnRNPA1 pathology ( Fig. 2m-p and Supplementary Fig. 4g , k). In these instances there was often partial co-localization of TDP-43, hnRNPA2B1 and hnRNPA1. We also observed limited immunopositivity for ubiquitin and p62 ( Supplementary Fig. 4l -o).
Disease mutations affect hnRNPA2B1 and A1 PrLDs hnRNPA2B1 and hnRNPA1 each have carboxy-terminal, glycine-rich domains that are essential for activity and mediate interaction with TDP-43 (ref. 8) . FoldIndex predicts these domains to be intrinsically unfolded ( Fig. 3a, b ). Interestingly, these low-complexity domains have an amino-acid composition similar to that of yeast prion domains. Indeed, a previously devised algorithm 14 predicted that the C-terminal regions of hnRNPA2 (residues 185-341) and hnRNPA1 (residues 186-320) are prion like ( Fig. 3a-d ), whereas these domains narrowly missed the cutoff for prion propensity according to a different algorithm 15 . Interestingly, similar PrLDs are present in many hnRNPs, including TDP-43 and FUS (Supplementary Fig. 5 and Supplementary Table 3 ). The disease-causing mutations fall at the centre of the predicted PrLD, and, according to both algorithms, are expected to enhance prion-like behaviour ( Fig. 3a, b ). We also examined hnRNPA2B1 and hnRNPA1 with ZipperDB, a structure-based threading algorithm, which scores six-amino-acid segments or their propensity to form two self-complementary beta strands termed 'steric zippers' that form the spine of amyloid fibrils 16 . Hexapeptides with Rosetta energy lower than 223 kcal mol 21 are predicted to form steric zippers, with lower energy predicting higher amyloidogenicity. ZipperDB predicted that disease mutations increase the potency of steric zipper motifs present in the PrLDs of hnRNPA2B1 and hnRNPA1 ( Fig. 3c-f ). This analysis is discussed in greater detail in Supplementary Fig. 6 . Taken together, multiple algorithms predict that the PrLDs of hnRNPA2B1 and hnRNPA1 are intrinsically disordered, but poised to access higher order self-templating structures. Notably, the disease mutations are centred within these PrLDs and are predicted to promote transition to an ordered structure.
Disease mutations accelerate hnRNP fibrillization
We directly tested the predictions that (1) hnRNPA2 and hnRNPA1 are prone to fibrillization and (2) that this property is enhanced by disease-causing mutations. First, we experimentally assessed the ZipperDB prediction for the impact of disease mutations on steric zipper motifs found in hnRNPA2B1 and hnRNPA1. Notably, the synthetic mutant hexapeptides of hnRNPA2B1(D290V) (Asn-Tyr-Asn-Val-Phe-Gly) and hnRNPA1(D262V) (Ser-Tyr-Asn-Val-Phe-Gly) rapidly assembled into amyloid fibrils, as shown by thioflavin T fluorescence and electron microscopy, whereas the corresponding wild-type peptides did not, even after several weeks ( Fig. 4a-d) . Thus, the disease-causing mutations in hnRNPA2B1 and hnRNPA1 generate highly amyloidogenic hexapeptides precisely as predicted. The more potent steric zippers that result from disease mutations are likely to be important for two reasons. First, introduction of similarly potent steric zippers is sufficient to force fibril formation, even in model proteins that do not ordinarily fibrillize 17 . Second, in hnRNPA1 and hnRNPA2 these potent steric zippers are centred in the intrinsically disordered PrLD and are thus available to make intermolecular contacts and drive fibril formation.
We next assessed the fibrillization propensity of full-length proteins. We purified bacterially expressed, glutathione S-transferasetagged wild-type and mutant hnRNPA2 and hnRNPA1 as soluble proteins under native conditions and assessed fibrillization by sedimentation analysis and electron microscopy. Wild-type hnRNPA2 and hnRNPA1 were both intrinsically aggregation prone with a lag phase of ,4 h ( Fig. 4e , g). Electron microscopy revealed that wild-type hnRNPA2 and hnRNPA1 form fibrils ( Fig. 4f, h) . The pronounced lag suggests that a critical rate-limiting step in hnRNPA2 and hnRNPA1 fibrillization is nucleation. Indeed, a small quantity (5% wt/wt) of preformed hnRNPA2 or hnRNPA1 fibrils greatly accelerated the assembly of hnRNPA2 or hnRNPA1, respectively ( Supplementary  Fig. 7a, e ). By contrast, preformed hnRNPA2 fibrils did not seed assembly of hnRNPA1 ( Supplementary Fig. 7e ). Likewise, pre-formed hnRNPA1 fibrils did not seed assembly of hnRNPA2 ( Supplementary  Fig. 7a ). Thus, wild-type hnRNPA1 and hnRNPA2 spontaneously form self-seeding fibrils.
Importantly, the disease mutations greatly accelerated hnRNPA2 and hnRNPA1 fibrillization ( Fig. 4e-h) . In all cases, the lag phase was curtailed and fibrillization was well advanced while the wild-type protein remained in lag phase. Thus, the disease-causing mutations directly promote nucleation of hnRNPA2 and hnRNPA1 into fibrils. Moreover, fibrils formed by hnRNPA2(D290V), hnRNPA1(D262V) and hnRNPA1(D262N) not only seeded their own assembly ( Supplementary Fig. 7b , f, g), but also promoted fibrillization of their respective wild-type counterparts ( Supplementary Fig. 7d , i). Neither hnRNPA2(D290V) fibrils nor hnRNPA1(D262V) fibrils seeded the assembly of TDP-43, another RNA-binding protein with a PrLD. . e-g, Immunohistochemical analysis of hnRNPA1 (red) in a normal muscle (e), a muscle biopsy from patient IV9 from family 2 (f) and a patient with MSP caused by a VCP mutation (R155H) (g). hnRNPA1 was cleared from nuclei and accumulated in cytoplasmic inclusions (f, g). h, In muscle tissue from patient IV9 (family 2), hnRNPA2B1 was cleared from nuclei and accumulated in cytoplasmic inclusions. (i-l) Immunohistochemical analysis of TDP-43 (red) in a normal muscle (i), muscle biopsy from patient II5 from family 1 (j), muscle biopsy from patient IV9 from family 2 (k) and a patient with MSP caused by a VCP mutation (R155H) (l). TDP-43 (red) was cleared from DAPI-stained nuclei (blue) and accumulated in cytoplasmic inclusions (jl). m-p, Immunohistochemical analysis of hnRNPA2B1 and TDP-43 colocalization in a patient with sporadic IBM. DAPI (m), TDP-43 (n), hnRNPA2B1 (o) and merged images (p) are shown. hnRNPA2B1 (red) and TDP-43 (green) were cleared from nuclei (arrowheads) in an atrophic muscle fibre, but found in nuclei of neighbouring unaffected fibres (arrows). Scale bars, 50 mm.
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Finally, we assessed the importance of the steric zipper motifs in fibrillization. We deleted the steric zipper residues 287-292 from hnRNPA2 and 259-264 from hnRNPA1 and assessed fibrillization in vitro. Importantly, neither hnRNPA2(D287-292) nor hnRNPA1(D259-264) formed fibrils ( Fig. 4e, g) , even after 24 h of agitation. Moreover, hnRNPA2(D287-292) did not fibrillize when seeded by fibrils of wild-type or mutant hnRNPA2 ( Supplementary  Fig. 7c ), nor did hnRNPA1(D259-264) fibrillize when seeded by fibrils of wild-type or mutant hnRNPA1 ( Supplementary Fig. 7h ). Thus, residues 287-292 of hnRNPA2 and 259-264 of hnRNPA1 are critical for spontaneous and seeded fibrillization of the full-length protein. Collectively, these findings indicate that steric zipper motifs centred in the PrLDs of wild-type hnRNPA2 and hnRNPA1 are critical to their intrinsic tendency to fibrillize and that disease mutations introduce more-potent steric zippers, which accelerate nucleation and polymerization ( Supplementary Fig. 6 ).
Mutant hnRNPA2B1 PrLD supports yeast prion activity
Yeast prion proteins are generally modular, meaning that prion domains from one protein can be transferred to another, while retaining prion activity 18 . To determine whether the PrLD of hnRNPA2B1 could support prion activity in yeast, we replaced the Sup35 nucleation domain (residues 3-40) with the core PrLD (residues 261-303) from either wild-type or mutant hnRNPA2B1 and expressed these fusion proteins as the sole copies of Sup35 in the cell. Prion formation was detected by monitoring nonsense suppression of the ade2-1 allele and verified by monitoring a series of prion-defining criteria, including curability with guanidine, transferability with cytoduction and sensitivity to expression levels (detailed in Supplementary Fig. 8 ). This analysis showed that the hnRNPA2B1 core PrLD can substitute for the Sup35 nucleation domain in supporting prion formation, and that the D290V mutation specifically promotes the nucleation activity. Moreover, full-length hnRNPA1 and hnRNPA2 form cytoplasmic aggregates and are toxic in yeast ( Supplementary Fig. 9 ).
Mutations enhance hnRNP recruitment to RNA granules
Remarkably, the PrLDs in hnRNPA2B1 and hnRNPA1 correspond to the 'low-complexity sequences' found in various hnRNPs (including TDP-43 and FUS) that are essential determinants of RNA granule assembly 19 . Stress granules are cytoplasmic ribonucleoprotein granules composed of repressed translation complexes 20, 21 . TDP-43 and FUS are recruited to stress granules and this is enhanced by disease mutations 20 . Thus, we proposed that hnRNPA2B1 and hnRNPA1 would be recruited to stress granules and that this would be enhanced by disease mutations. To test this, we first examined the subcellular localization of endogenous hnRNPA2B1 in HeLa cells before and after stress granule induction with arsenite. At baseline, endogenous hnRNPA2B1 was localized exclusively to nuclei ( Supplementary  Fig. 10 ). After arsenite treatment hnRNPA2B1 re-localized to eIF4G-positive cytoplasmic puncta, showing the recruitment of endogenous hnRNPA2B1 to stress granules ( Supplementary Fig. 10 ).
To examine the impact of disease mutations, we expressed Flagtagged versions of wild-type and mutant hnRNPA2. There was significantly greater incorporation of mutant hnRNPA2 into constitutive stress granules than wild-type hnRNPA2 (Fig. 5a ). Moreover, after arsenite treatment mutant hnRNPA2 was incorporated into stress granules more rapidly than wild-type hnRNPA2, although by 30 min their degree of incorporation was similar (Fig. 5b) . Both wild-type and mutant hnRNPA2 formed high-molecular-weight species that accumulated in the detergent-insoluble fraction (Fig. 5c ). Similar to the kinetics of stress granule incorporation, mutant hnRNPA2 accumulated as high-molecular-weight species more rapidly than wild-type hnRNPA2, although by 30 min their accumulation was comparable ( Fig. 5c ). Similar results were obtained upon examination of endogenous hnRNPA1 as well as exogenous wild-type and mutant hnRNPA1 ( Supplementary Fig. 11 ). Interestingly, hnRNPA2-positive and hnRNPA1-positive stress granules were also immunopositive for TDP-43 ( Supplementary Fig. 12 ). We also generated fibroblast cell lines from patients II4 and II6 (family 1). In these cells endogenous mutant hnRNPA2 accumulated in constitutive stress granules that were immunopositive for eIF4G in addition to TDP-43 and VCP ( Supplementary Fig. 13 ).
Mutant hnRNPs form pathological inclusions in vivo
We generated transgenic Drosophila expressing wild-type or mutant forms of human hnRNPA2 and hnRNPA1, as well as wild-type or mutant forms of the fly homologue HRB98DE ( Supplementary  Figs 14 and 15 ). Expression of wild-type hnRNPA2 in Drosophila . These regions were also predicted to be prion-like according to their log-likelihood ratio scores (PrD LLR) from the algorithm described in ref. 14 (red curve less than zero), and narrowly missed the cutoff for the predicted prion propensity (PPP) log-odds ratio scores from the algorithm described in ref. 15 (green curve below the dashed green line). All curves represent averages of 41 consecutive windows of 41 amino acids, corresponding to the criteria described in ref. 15 . The disease mutations were predicted to make these domains more prionogenic (insets). c, d, ZipperDB-detected six-amino-acid stretches (underlined in e, f) within the core PrLDs for which the disease mutations increased the predicted amyloid-fibril-forming potential beyond the Rosetta threshold. e, f, Domain architecture of hnRNPA2 (e) and hnRNPA1 (f) shows the RNArecognition motifs 1 and 2 (RRM1 and RRM2), the C-terminal glycine-rich domain and an M9 nuclear-localization signal. The PrLDs are centred in the C-terminal glycine-rich domain. Highly similar predictions were made for the minor isoforms of hnRNPA2B1 (hnRNPB1) and hnRNPA1 (hnRNPA1 isoform b). WT, wild type.
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indirect flight muscle led to mild degeneration affecting the rostral portion of several muscles, whereas expression of hnRNPA2(D290V) caused severe degeneration that affected all muscles (Fig. 6a ). Importantly, flies overexpressing hnRNPA2(D287-292), in which the hexapeptide (Asn-Tyr-Asn-Asp/Val-Phe-Gly) in the PrLD was deleted, had virtually normal muscles (Fig. 6a ). This result indicates that the severe toxicity found in flies overexpressing mutant hnRNPA2 requires the presence of this potent steric zipper motif. Immunohistochemical analysis showed that wild-type hnRNPA2 localized appropriately to nuclei, as did hnRNPA2(D287-292), whereas hnRNPA2(D290V) largely accumulated in cytoplasmic inclusions (Fig. 6b ). We observed a correlation between cytoplasmic inclusion formation and solubility of hnRNPA2. Specifically, mutant hnRNPA2(D290V) protein was largely recovered from the detergentinsoluble fraction, whereas wild-type hnRNPA2 and hnRNPA2(D287-292) proteins were mostly found in the detergent-soluble fraction (Fig. 6c, d) . Thus, the degree of muscle degeneration in flies expressing hnRNPA2 correlates with the extent of cytoplasmic inclusions and with hnRNPA2 solubility. Entirely consistent results were obtained upon expression of wild-type and mutant versions of hnRNPA1 and HRB98DE ( Supplementary Fig. 15 ).
Last, we evaluated the impact of the disease mutation on hnRNPA2 cellular localization in mammalian muscle. We electroporated mouse tibialis anterior with plasmid expressing Flag-tagged versions of wild-type or mutant hnRNPA2. Wild-type hnRNPA2 was localized appropriately within nuclei, whereas mutant hnRNPA2(D290V) was excluded from nuclei and accumulated in cytoplasmic inclusions ( Supplementary Fig. 16 ), highly reminiscent of the pathology seen in MSP patients.
Discussion
Polymerization of PrLDs underlies the orderly, regulated phase transition that drives assembly of non-membrane-bound organelles including RNA granules, which serve as 'reaction crucibles' in which many aspects of RNA metabolism occur 22 . Disease mutations introduce more potent steric zippers into the PrLDs of hnRNPA2 and hnRNPA1, dysregulating and accelerating nucleation and polymerization, altering the dynamics of RNA granule assembly, which likely has adverse consequences for RNA metabolism. In addition to hnRNPA2 and hnRNPA1, at least four other RNA-binding proteins that harbour PrLDs (TDP-43, FUS, EWSR1 and TAF15) accumulate in disease pathology 23 . By analogy to hnRNPA2B1 and hnRNPA1, we speculate that these and perhaps other PrLD-containing proteins contribute to the initiation or propagation of disease by a similar mechanism. Indeed, ,250 human proteins are predicted to harbour PrLDs, many of which are RNA-binding proteins ( Supplementary Fig. 5 and Supplementary Table 3 ), and should be considered candidates for contributing to degenerative disease.
Thus, disease could ensue from unregulated polymerization initiated spontaneously by PrLDs upon environmental stress, or by a mutation affecting either the PrLD or another factor (for example, VCP) that regulates the ribonucleoprotein granule assembly with altered metabolism of RNA as a consequence. 
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Notably, diseases associated with pathological inclusions of PrLDcontaining proteins frequently show 'spreading' pathology, in which cellular degeneration with intracellular inclusions starts in one epicentre and subsequently spreads to neighbouring tissue 24 . Although not directly addressed here, this study suggests that cell-to-cell transmission of a self-templating conformer could contribute to the spreading pathology that is characteristic of these diseases.
The discovery of VCP mutations in MSP 1 led to the subsequent discovery of pathogenic VCP mutations in sporadic or familial forms of ALS 2 , FTD 4 , IBM 5 and PDB 6 . Therefore, subsequent to the discovery of mutations in hnRNPA2B1 and hnRNPA1 underlying MSP, we screened 212 familial ALS cases and identified a pathogenic hnRNPA1 mutation in one family, as described earlier. As this manuscript was being assembled for publication we completed screening of 305 sporadic ALS cases and identified a non-synonymous variant in hnRNPA1 (c.800/956A.G, p.N267S/N319S) in one classic, lateonset case in which mutations in known ALS genes had been excluded ( Supplementary Fig. 17 ). Although not definitive, this variant is probably pathogenic because it is centred in the core PrLD and introduces a potent steric zipper similar to that introduced by D262V/N mutations. The frequency of hnRNPA2B1 and hnRNPA1 mutations in ALS, and the possibility that mutations in these genes underlie some sporadic and familial forms of FTD, IBM and PDB, will be important to address in the future.
METHODS SUMMARY
Exome enrichment of 3 mg genomic DNA was performed by using the Agilent SureSelect Human All Exon Kit capture library (G3362 for five DNA samples from family 1 and G3370 for five DNA samples from family 2) according to the manufacturer's protocol (SureSelect Human All Exon Illumina Paired-End protocol version 1.0.1). Captured DNAs were sequenced on an Illumina GAIIx sequencer (Illumina) with 76-base-pair (family 1) or 100-base pair (family 2) paired-end reads. At least two lanes of sequencing data were collected for each sample to generate sufficient coverage. Image analyses and base calling were performed by using the Illumina Genome Analyzer Pipeline software (GAPipeline version 1.5 or higher) with default parameters. Reads were aligned to a human reference sequence (University of California, Santa Cruz (UCSC) assembly hg19, National Center for Biotechnology Information (NCBI) build 37) and genotypes were called at all positions at which there were high-quality sequence bases (Phredlike score Q25 or greater) at minimum coverage of 8, using CLC Genomics Workbench v4.5.1 (CLC Bio). For each sample, more than 50% of at least 100 million reads were uniquely mapped to the targeted human exon regions to give mean depth of coverage of 123. For linkage analysis samples were genotyped using the Affymetrix Genome-Wide Human SNP Array 6.0. Single nucleotide polymorphism genotype calls were performed according to the standard Affymetrix protocols. A subset of single nucleotide polymorphisms chosen on the basis of heterozygosity was used for linkage analysis, using dChip software (http:// www.hsph.harvard.edu/cli/complab/dchip/) under parametric linkage analysis and a dominant model with 99% penetrance in heterozygotes and a disease allele frequency of 0.001. Reads were aligned to a human reference sequence (UCSC assembly hg19, NCBI build 37) and genotypes were called at all positions at which there were highquality sequence bases (Phred-like score Q25 or greater) at minimum coverage of 8, using CLC Genomics Workbench v4.5.1 (CLC Bio). For each sample, more than 50% of at least 100 million reads were uniquely mapped to the targeted human exon regions to give a mean depth of coverage of 123. Under such coverage, approximately 94% of targeted regions were covered by 5 reads or more, and more than 85% were covered by more than 20 reads ( Supplementary Fig. 1 ). To identify the pathogenic mutations, we performed a series of filtering steps ( Supplementary  Fig. 1 ). We first discarded the variants that did not change the amino-acid sequence. We then generated a list of variants that are present in affected individuals but absent in nonaffected individuals. Variants previously reported in the Single Nucleotide Polymorphism Database build 132 (dbSNP132) hosted by the National Center for Biotechnology Information were excluded. The variants were further filtered by using the in-house database (a collection of variants from whole-exome sequencing of more than 625 individuals) by a similar methodology. Finally Sanger sequencing was performed on DNA of three additional members (both affected and nonaffected) from each family to exclude the nonpathogenic mutations. Presence of mutations was confirmed in all candidate disease-causing variants by Sanger sequencing. Linkage analysis. Eight DNA samples (parents and six siblings) from family 1 were genotyped using the Affymetrix Genome-Wide Human SNP Array 6.0. SNP genotype calls were performed according to the standard Affymetrix protocols. A subset of SNPs chosen on the basis of heterozygosity was used for linkage analysis, using dChip software (http://www.hsph.harvard.edu/cli/complab/dchip) under parametric linkage analysis and a dominant model with 99% penetrance in heterozygotes and a disease allele frequency of 0.001. Five genomic segments with a size greater than 100 kilobases, at least 20 SNP markers, and a log odds ratio (lod) score greater than 0 are shown in Supplementary Fig. 1 . Generation of phylogram for hnRNP A/B gene family. TBPH of D. melanogaster was used to BLAST (basic local alignment search tool) against the RefSeq protein database including species of M. musculus, D. melanogaster, A. gambiae, H. sapiens, D. rerio (zebrafish), C. elegans and G. gallus (jungle fowl). The top 100 sequences (according to BLAST E values) were obtained. Sequences sharing more than 98% similarity were filtered by UCLUST 25 because they likely represent alternatively spliced variants of the same genes. Eighty-one sequences remaining after this process were aligned using the MAFFT multiple sequence alignment program 26 . The DNA-coding sequences of all proteins were extracted and threaded onto the protein sequences to form an in-frame codon alignment. Squint 27 was used to extract the DNA-coding alignment of the two RRM domains present in each protein using the protein alignment as a guide. Phylogenetic trees of the codon alignment including 21 genes from only human and Drosophila were generated using the genetic algorithm-based GARLI 28 method.
Constructs. Complementary DNAs encoding human hnRNPA2 (accession number NM_002137.2) or hnRNPA1 (accession number NM_002136.1) in the plasmid pCMV6-XL5 were obtained from OriGene. A Flag epitope tag was added to the 59 end of hnRNPA2 or hnRNPA1 by PCR. The cDNAs were then subcloned into a pcDNA 3.1 plasmid, using restriction sites EcoRI and XhoI, creating pcDNA 3.1-Flag-hnRNPA2 or -Flag-hnRNPA1. cDNAs encoding Drosophila HRB98DE (accession number NM_170373.1) were obtained from the Drosophila Genomics Research Center. Missense mutations of hnRNPA2 (hnRNPA2 (D290V)), hnRNPA1 (hnRNPA1(D262V)) and Drosophila HRB98DE (HRB98DE (D302V)) were generated by site-directed mutagenesis. Sequence analysis was conducted on all plasmid constructs.
Antibodies. The following commercial antibodies were used in this study: mouse monoclonal anti-hnRNPA2B1 antibodies EF-67 and DP3B3 (Santa Cruz Biotechnology), rabbit polyclonal anti-TDP-43 antibody (Protein Tech Group), anti-eIF4G antibody (Santa Cruz Biotechnology), anti-hnRNPA1 antibody (Cell Signaling Technology), anti-VCP antibody (Epitomics) and anti-Flag M2 antibody (Sigma). Anti-hnRNPA1 antibodies (4B10 and 9H10) were generous gifts from G. Dreyfuss. Validation of these antibodies is shown in Supplementary Fig. 18 . Immunofluorescence studies. Cells were fixed in 4% paraformaldehyde in PBS buffer, permeabilized with 0.5% Triton X-100 in PBS for 10 min, blocked with 5% goat serum in PBS for 30 min and incubated with primary antibody for 2 h at room temperature (20-25 uC) or overnight at 4 uC. Primary antibodies were visualized with secondary antibodies conjugated with Alexa Fluor 488 and Alexa Fluor 594 (Molecular Probes, Invitrogen) and nuclei were detected using DAPI. Stained cells were examined using a confocal microscope (Zeiss LSM 510 NLO Meta) with Zeiss ZEN software. Solubility and biochemical analyses. Sequential extractions were performed to examine the solubility profile of hnRNPA2B1. Cells were washed twice with PBS, lysed in cold RIPA buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS and 1 mM EDTA) and sonicated. Cell lysates were cleared by centrifugation at 100,000g for 30 min at 4 uC to generate RIPA-soluble samples. To prevent carry-overs, the resulting pellets were washed twice with PBS (that is, re-sonicated and re-centrifuged). Only supernatants from the first centrifugation were analysed. RIPA-insoluble pellets were then extracted with urea buffer (7 M urea, 2 M thiourea, 4% CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulphonate), 30 mM Tris, pH 8.5), sonicated and centrifuged at 100,000g for 30 min at 22 uC. Protease inhibitors were added to all buffers before use. Protein concentration was determined by the bicinchoninic acid method (Pierce) and proteins were resolved by NuPAGE Novex 4-12% Bis-Tris Gel (Invitrogen).
In vivo electroporation of mice. All animal work was performed with the approval of the St Jude Children's Research Hospital Committee on Animal Care. Mice were anesthetized and the skin overlying the tibialis anterior muscle was shaved, and the animals were injected with endotoxin-free Flag-tagged wildtype hnRNPA2 or Flag-tagged hnRNPA2(D290V) mutant diluted in sterile PBS to a volume of 50 ml by using a 0.5-ml syringe fitted with a 29-gauge needle. Two-needle array electrodes (BTX Technologies) were inserted into the muscle immediately after DNA delivery for electroporation. The distance between the electrodes was 5 mm, and the array was inserted longitudinally relative to the muscle fibres. In vivo electroporation parameters were as follows: voltage, 75 V; pulse length, 50 ms; number of pulses, 6; pulse interval, 200 ms; desired field strength, 200 V cm 21 , given by a BTX ECM830 Electro Square Porator. After 7 days of recovery, mice were processed for immunofluorescence analysis.
Muscle histochemistry and immunohistochemistry. Human samples were processed for routine histochemical analysis as previously described 13 . For skeletal muscle immunohistochemistry, isolated skeletal muscle was mounted by using tragacanth gum and quick-frozen in liquid-nitrogen-cooled 2-methylbutane. Sections (8 mm) were placed on slides and fixed in 4% paraformaldehyde for 5 min and then ice-cold acetone for 5 min. Sections were incubated with PNB blocking reagent (Perkin Elmer) for 1 h and then incubated overnight in primary antibody diluted in PNB. After serial washes in 13 PBS, slides were incubated in secondary antibody diluted in PNB for 2 h. Sections were mounted with Mowiol containing DAPI. Specimens were examined using a fluorescent microscope (80i upright; Nikon) and charge-coupled device camera (EZ monochrome; Roper Industries) with deconvolution software analysis (NIS Elements; Nikon). Nonfluorescent images were taken with a 5-megapixel colour charge-coupled RESEARCH ARTICLE
